1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
14.48(c) 14.78(c) 14.46(c) 14.8(c) 14.94 Last
944 500 1 203 500 595 953 565 500 480 419 Volume
-3.85% +2.07% -2.17% +2.35% +0.95% Change
More quotes
Estimated financial data (e)
Sales 2022 644 M 95,5 M 95,5 M
Net income 2022 -308 M -45,6 M -45,6 M
Net cash position 2022 2 543 M 377 M 377 M
P/E ratio 2022 -20,3x
Yield 2022 -
Sales 2023 1 020 M 151 M 151 M
Net income 2023 -228 M -33,8 M -33,8 M
Net cash position 2023 2 140 M 317 M 317 M
P/E ratio 2023 -28,2x
Yield 2023 -
Capitalization 5 573 M 826 M 826 M
EV / Sales 2022 4,70x
EV / Sales 2023 3,37x
Nbr of Employees 905
Free-Float 79,7%
More Financials
Company
Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and... 
More about the company
Ratings of Venus Medtech (Hangzhou) Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VENUS MEDTECH (HANGZHOU) INC.
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's..
CI
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
MT
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
06/22Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Com..
CI
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Comple..
CI
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
MT
03/31VENUS MEDTECH ANNOUNCES 2021 ANNUAL : pacesetter in China and breakthrough-maker worldwid..
AQ
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/21Atom Semiconductor announced that it has received $15.8 million in funding from Gobi Pa..
CI
03/18Venus Medtech Inc. Appoints Shakeel Osman as Senior Vice President of Sales Europe
CI
03/18Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercializ..
AQ
03/02Venus Medtech to Build Israel Center for New Heart Valve Technologies Development; Shar..
MT
03/01Venus Medtech Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation C..
CI
03/01Venus Medtech Inc. Announces Establish of Venus Global Heart Valve Innovation Center
CI
More news
News in other languages on VENUS MEDTECH (HANGZHOU) INC.
07/13L'Administration nationale des produits médicaux de Chine approuve Venusp-Valve, le sys..
06/22Venus Medtech (Hangzhou) Inc. Annonce le premier patient américain traité avec VenusP-V..
04/12Venus Medtech (Hangzhou) Inc. annonce que la valve bioprothétique expansible en tissu s..
03/31Venus Medtech (Hangzhou) Inc. annonce ses résultats pour l'année complète se terminant ..
03/18Venus Medtech (Hangzhou) Inc. nomme Shakeel Osman au poste de vice-président principal ..
More news
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 12,73 CNY
Average target price 21,62 CNY
Spread / Average Target 69,9%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Hai Yue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VENUS MEDTECH (HANGZHOU) INC.-50.00%826
STRYKER CORPORATION-18.48%82 928
SMITH & NEPHEW PLC-17.70%11 371
INSPIRE MEDICAL SYSTEMS, INC.-1.56%6 178
AXONICS, INC.25.14%3 488
GLAUKOS CORPORATION12.51%2 396